伊犁川宁生物技术股份有限公司 2023 年半年度报告全文 伊犁川宁生物技术股份有限公司 2023 年半年度报告 新疆 伊犁 2023 年 08 月 1 伊犁川宁生物技术股份有限公司 2023 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人邓旭衡、主管会计工作负责人李懿行及会计机构负责人(会计 主管人员)牛砚声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 伊犁川宁生物技术股份有限公司 2023 年半年度报告全文 | --- | |-----------------------------------------------------------------------------------------------------------------------| | 目录 第一节 重要提示、目录和释义 ·············· ...

证券代码：301301 证券简称：川宁生物 | --- | --- | --- | |--------------|-----------------|-------------| | | 特定对象调研 | □分析师会议 | | | □媒体采访 | ☐业绩说明会 | | 投资者关系 | | | | | □新闻发布会 | □路演活动 | | 活动类别 | | | | | 现场参观 | | | | □其他：电话调研 | | | | | | | 参与单位名称 | | | | 及人员姓名 | | | 计 25 人次。 时间 2023 年 7 月 13 日（周四）上午 10:00~13:00 地点 公司四楼会议室 上市公司接待 1、董事会秘书顾祥 人员姓名 2、证券事务专员王乐 1、公司为什么会选址在伊犁地区？ 新疆伊犁地区拥有地理、资源、气候、区位等优势，公 司可以从多维度降低生产成本，使公司产品在激烈的市场竞 争中更具成本优势。 气候方面：公司地处伊犁河谷，当地具有适合生物发酵 的温度、湿度等气候条件，适宜的气候条件能够提高发酵水 平，进而降低公司的生产成本。 原料方面：公司所在地拥有丰富的水资源和煤炭资源、 投资 ...

证券代码：301301 证券简称：川宁生物 伊犁川宁生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |--------------|-----------------|-------------|------------| | | | | 编号：0004 | | | ☐特定对象调研 | □分析师会议 | | | | □媒体采访 | 业绩说明会 | | | 投资者关系 | | | | | | □新闻发布会 | □路演活动 | | | 活动类别 | | | | | | ☐现场参观 | | | | | □其他：电话调研 | | | | 参与单位名称 | 投资者网上提问 | | | 及人员姓名 时间 2023 年 6 月 16 日（周五）下午 15:00~18:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会 上市公司接待 1、董事会秘书顾祥 2、证券事务专员王乐 人员姓名 1、2023 年二季度业绩预计怎么样？ 尊敬的投资者，您好！公司目前经营情况良好。第二季 度具体经营情况将在 2023 年半年 ...

证券代码：301301 证券简称：川宁生物 公告编号：2023-043 伊犁川宁生物技术股份有限公司 关于参加新疆辖区上市公司2023年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，伊犁川宁生物技术股份有限公司（以下 简称"公司"）将参加由新疆证监局、新疆上市公司协会与深圳市全景网络有限 公司联合举办的"2023 年新疆辖区上市公司投资者集体接待日活动"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 6 月 16 日（周五）15:30-18:00。届时公司 高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告。 伊犁川宁生物技术股份有限公司董事会 2023 年 6 月 6 日 ...

证券代码：301301 证券简称：川宁生物 | --- | --- | --- | |--------------|-----------------------|-------------| | | 特定对象调研 | □分析师会议 | | | □媒体采访 ☐ | 业绩说明会 | | 投资者关系 | | | | | □新闻发布会 | □路演活动 | | 活动类别 | | | | | 现场参观 | | | | □其他：电话调研 | | | | | | | | | | | | | | | | | | | | | | | | | | | 参与单位名称 | | | | | | | | 及人员姓名 | | | | | | | | | | | | | | | | | | | | | 券报、21 世纪经济报、 | E | | | 投资者、媒体共计 | 75 人次。 | 时间 2023 年 5 月 25 日 10:00-12:30 地点 公司 5 楼会议室 董事、总经理邓旭衡先生；董事、副总经理、财务总监李懿 上市公司接待 行先生；副总经理、首席科学家赵华先生、副总经理、董事 人员姓名 会秘书顾祥先生。 伊犁川宁生物技术股份 ...

证券代码：301301 证券简称：川宁生物 伊犁川宁生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|-----------------|-----------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | 活动类别 | | | | | □现场参观 | | | | □其他：电话调研 | | | 参与单位名称 | | | | 及人员姓名 | （网址： | https://eseb.cn/14yPfeAv1hm | 时间 2023 年 5 月 15 日 16:00-17:00 地点 价值在线（https://www.ir-online.cn/）网络互动 董事、总经理邓旭衡先生；董事、副总经理、财务总监李懿 上市公司接待 行先生；副总经理、董事会秘书顾祥先生；副总经理、销售 总监姜海先生；副总经理、首席科学家赵华先生；独立董事 人员姓名 段宏女士；长江证券保荐代表人李忠先生。 1.恭喜公司 22 年营收、净利润双增长， ...

伊犁川宁生物技术股份有限公司 2023 年第一季度报告 伊犁川宁生物技术股份有限公司 2023 年第一季度报告 新疆 伊犁 2023 年 04 月 1 伊犁川宁生物技术股份有限公司 2023 年第一季度报告 | --- | --- | --- | |----------------------|-------------------------------------------------------------------------------|---------------------| | 证券代码： 301301 | 证券简称：川宁生物 \n伊犁川宁生物技术股份有限公司 \n2023 年第一季度报告 | 公告编号： 2023-031 | | 导性陈述或重大遗漏。 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 | | 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务 ...

Financial Performance - The company's operating revenue for 2022 was ¥3,820,657,857.71, an increase of 18.21% compared to ¥3,232,014,638.04 in 2021[11]. - The net profit attributable to shareholders for 2022 was ¥411,518,024.65, representing a significant increase of 269.58% from ¥111,346,659.27 in 2021[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥446,630,289.76, up 147.15% from ¥180,710,589.01 in 2021[11]. - The company's cash flow from operating activities for 2022 was ¥691,638,049.25, a decrease of 13.89% compared to ¥803,211,175.51 in 2021[11]. - The basic earnings per share for 2022 was ¥0.21, a 250.00% increase from ¥0.06 in 2021[11]. - The total assets at the end of 2022 were ¥10,390,399,359.24, reflecting a growth of 9.82% from ¥9,461,536,586.60 at the end of 2021[11]. - The net assets attributable to shareholders at the end of 2022 were ¥6,204,485,260.20, an increase of 30.04% from ¥4,771,284,144.72 at the end of 2021[11]. - The company achieved a total revenue of 606.76 million CNY for the reporting period[147]. - The total operating income of the evaluated units accounted for 97.74% of the company's consolidated financial statement operating income[165]. Dividend Policy - The company plans to distribute a cash dividend of 0.93 CNY per 10 shares to all shareholders, based on a total of 222,280,000 shares[2]. - The net profit attributable to shareholders reached RMB 412 million, a significant increase of 269.58% compared to the previous year[55]. - The company achieved a net profit attributable to shareholders of 411,518,024.65 CNY for the year 2022, with a profit distribution plan proposing a cash dividend of 0.93 CNY per 10 shares, totaling 206,720,400.00 CNY, which represents 50.23% of the net profit[161]. - The total distributable profit at the end of 2022 was 666,044,232.52 CNY, with retained earnings of 459,323,832.52 CNY to be carried forward for future distribution[161]. - The company has committed to a three-year dividend return plan to actively reward investors and protect the rights of minority shareholders[158]. Research and Development - The company reported a significant focus on research and development, with potential risks including industry policy changes and market risks[2]. - The company has established a comprehensive synthetic biology platform that includes a computational biology strain design platform and an automated high-throughput strain construction and screening platform, significantly improving R&D efficiency[31]. - The total R&D investment for 2022 was ¥35,381,740.73, accounting for 0.93% of operating revenue, a decrease from 1.41% in 2021[77]. - Research and development expenses increased by 7.37% to ¥35,381,740.73, indicating ongoing investment in innovation[72]. - The number of R&D personnel increased to 132 in 2022, representing a growth of 6.45% compared to 124 in 2021[76]. - The company is advancing several R&D projects aimed at enhancing product lines and market competitiveness, including the development of 7-ADCA through biotechnological methods[73]. Market Position and Strategy - The company holds a 43.86% market share in the thiocyanate erythromycin market, with an annual production capacity of approximately 3,000 tons, ranking second in the industry[25]. - In the cephalosporin intermediate market, the company has a total production capacity of about 3,000 tons per year, with a market share of 37.00%, making it the industry leader[25]. - The company's penicillin intermediate production capacity is approximately 6,700 tons per year, holding an 18.00% market share, ranking second in the industry[25]. - The company is positioned as a leading enterprise in the antibiotic intermediate market, benefiting from a robust industrial production system[25]. - The company aims to transition from resource-driven to technology-driven growth, enhancing its operational efficiency and market competitiveness[33]. Governance and Compliance - The company has established a strong governance structure with a board of directors and supervisory board ensuring accountability[3]. - The board of directors consists of 7 members, including 3 independent directors, and held 6 meetings during the reporting period[113]. - The company has established several engineering technology centers and has been recognized as a model for green manufacturing and intelligent manufacturing[39]. - The company has a clear and complete asset ownership structure, with no reliance on the controlling shareholder or related entities[123]. - The company has established an independent financial department and maintains a separate bank account, ensuring no shared accounts with the controlling shareholder[126]. Environmental Responsibility - The company has invested nearly 2.5 billion yuan in environmental protection facilities, accounting for over 25% of total project investment[49]. - The company has developed a project for the regeneration of saturated granular activated carbon, utilizing clean fuel biogas from its wastewater treatment system[176]. - The company has established multiple environmental management systems to ensure effective waste treatment and compliance with environmental standards[169]. - The company is actively responding to national carbon peak and carbon neutrality goals, establishing a greenhouse gas emission management system[176]. - The company has implemented strict environmental standards and continuously increases investment in environmental protection[179]. Risk Management - The company has a comprehensive risk management strategy to address environmental, quality control, and innovation risks[2]. - The company aims to mitigate foreign exchange risks through hedging strategies, ensuring compliance with relevant regulations and internal controls[89]. - The risk control measures include avoiding speculative trading and focusing on hedging to protect against significant currency fluctuations[89]. - The company has established a management system for foreign exchange hedging, detailing operational procedures, approval authority, and risk reporting mechanisms[89]. Investment and Financing - The total amount of funds raised in the IPO was RMB 1,114 million, with a net amount of RMB 1,021 million after deducting expenses[90]. - The company has committed to invest RMB 60 million in projects, with RMB 40 million already utilized for repaying bank loans, achieving a 100% investment progress[92]. - The financing activities generated a net cash flow of ¥475,923,386.14, a significant increase of 163.52% compared to the previous year, primarily due to public share issuance[78]. Community Engagement - The company actively supports rural revitalization by purchasing local agricultural products, employing over 40 villagers from the Yingyeer Village[185]. - The company has participated in the "Hundred Enterprises Help Hundred Villages" initiative, focusing on practical assistance and job creation for local residents[185]. - The company has made significant contributions to poverty alleviation efforts in Xinjiang, enhancing social stability and economic development[185].